Asia Pacific Biosimilars 麻豆原创 2020-2030 by Product Type, Indication, Manufacturing (Contract, Inhouse), End User, and Country: Trend Forecast and Growth Opportunity

Publication ID:

GRM1121024

Publication Date:

November 30, 2021

Pages:

116

Publisher:

Grace 麻豆原创 Data

Countries:

Asia Pacific [1]

USD 2,700.00

Pharmaceutical Manufacturing [2]

Pharmacy [3]

Country Overview (Pharma & Healthcare) [4]

Pharma & Healthcare [5]

Description:

Asia Pacific biosimilars market will grow by 30.7% annually with a total addressable market cap of $140.4 billion over 2021-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.
Highlighted with 33 tables and 56 figures, this 116-page report 鈥淎sia Pacific Biosimilars 麻豆原创 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire Asia Pacific biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country.

Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
鈥� Recombinant Non-glycosylated Biosimilars
o Insulin
o Recombinant Human Growth Hormone (rHGH)
o Granulocyte Colony Stimulating Factor
o Interferon
鈥� Recombinant Glycosylated Biosimilars
o Monoclonal Antibodies (mAb)
o Erythropoietin (EPO)
o Follicle Stimulating Hormone
鈥� Recombinant Peptides and Others
o Tumor Necrosis Factor (TNF)-Inhibitor
o Parathyroid Hormone
o Enzymes, Immunomodulators, GnRH Analogs and Others

Based on Indication, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
鈥� Cancer
鈥� Autoimmune Disease
鈥� Blood Disorder
鈥� Diabetes
鈥� Growth Hormone Deficiency
鈥� Infectious Diseases
鈥� Other Indications

Based on Manufacturing, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
鈥� Contract Manufacturing
鈥� Inhouse Manufacturing

Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.
鈥� Hospitals and Clinics
鈥� Research Institutes
鈥� Other End Users

Geographically, the following national/local markets are fully investigated:
鈥� Japan
鈥� China
鈥� South Korea
鈥� Australia
鈥� India
鈥� Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy鈥檚 Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of 麻豆原创 Research Methodology 11
1.2.2 麻豆原创 Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 麻豆原创 Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 麻豆原创 Overview and Dynamics 19
2.1 麻豆原创 Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the 麻豆原创 25
2.2 Major Growth Drivers 27
2.3 麻豆原创 Restraints and Challenges 32
2.4 Emerging Opportunities and 麻豆原创 Trends 35
2.5 Porter鈥檚 Fiver Forces Analysis 39
3 Segmentation of Asia Pacific 麻豆原创 by Product Type 43
3.1 麻豆原创 Overview by Product Type 43
3.2 Recombinant Non-glycosylated Biosimilars 45
3.2.1 Insulin 47
3.2.2 Recombinant Human Growth Hormone (rHGH) 48
3.2.3 Granulocyte Colony Stimulating Factor 49
3.2.4 Interferon 50
3.3 Recombinant Glycosylated Biosimilars 51
3.3.1 Monoclonal Antibodies (mAb) 52
3.3.2 Erythropoietin (EPO) 53
3.3.3 Follicle Stimulating Hormone 54
3.4 Recombinant Peptides and Others 55
3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor 56
3.4.2 Parathyroid Hormone 57
3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others 58
4 Segmentation of Asia Pacific 麻豆原创 by Indication 59
4.1 麻豆原创 Overview by Indication 59
4.2 Cancer 61
4.3 Autoimmune Disease 62
4.4 Blood Disorder 63
4.5 Diabetes 64
4.6 Growth Hormone Deficiency 65
4.7 Infectious Diseases 66
4.8 Other Indications 67
5 Segmentation of Asia Pacific 麻豆原创 by Manufacturing 68
5.1 麻豆原创 Overview by Manufacturing 68
5.2 Contract Manufacturing 70
5.3 Inhouse Manufacturing 71
6 Segmentation of Asia Pacific 麻豆原创 by End User 72
6.1 麻豆原创 Overview by End User 72
6.2 Hospitals and Clinics 74
6.3 Research Institutes 75
6.4 Other End Users 76
7 Asia-Pacific 麻豆原创 2019-2030 by Country 77
7.1 Overview of Asia-Pacific 麻豆原创 77
7.2 Japan 80
7.3 China 83
7.4 Australia 85
7.5 India 87
7.6 South Korea 89
7.7 Rest of APAC Region 91
8 Competitive Landscape 93
8.1 Overview of Key Vendors 93
8.2 New Product Launch, Partnership, Investment, and M&A 97
8.3 Company Profiles 98
AMEGA Biotech S.A. 98
Apotex Inc. 100
Biocon Ltd 101
Biogen Inc. 102
Boehringer Ingelheim 103
Celltrion, Inc. 104
Dr. Reddy鈥檚 Laboratories Ltd. 105
Eli Lilly and Company 106
Intas Pharmaceuticals Ltd. 107
LG Chem, Ltd. 108
Merck and Co. Inc. 109
Mylan N.V. 110
Pfizer Inc. 111
Samsung Biologics Co., Ltd. 112
Sandoz International GmbH 113
STADA Arzneimittel AG 114
Teva Pharmaceutical Industries Ltd. 115
RELATED REPORTS 116

Companies Mentioned:

Key Players (this may not be a complete list and extra companies can be added upon request):
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy鈥檚 Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.